Jubilant Pharmova Q4 FY26 Results: PAT Rs 119 Cr
- May 22, 2026
- Posted by: Kashish Aggarwal
- Category: News
Jubilant Pharmova Q4 FY26 results were declared on May 22, 2026. The company reported PAT of Rs 119 crore for the quarter ended March 31, 2026, down 21.0% YoY compared to Rs 151 crore in Q4 FY25. Revenue from operations was Rs 2,290 crore, up 18.0% YoY. Results are on a Consolidated basis. Jubilant Pharmova is a Pharmaceuticals and Contract Manufacturing company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Jubilant Pharmova Q4 FY26 Financial Highlights
| Metric | Q4 FY26 (Rs Cr) | Q4 FY25 (Rs Cr) | YoY Change |
|---|---|---|---|
| Revenue | Rs 2,290 crore | Rs 1,929 crore | +18.0% |
| Gross Profit | Rs 223 crore | Rs 250 crore | -10.0% |
| Net Profit | 119 | 151 | -21.0% |
| Basis | Consolidated | ||
Note: Jubilant Pharmova Q4 FY26 results declared May 22, 2026. Verify from BSE/NSE audited filings before investment decisions.
Jubilant Pharmova Q4 FY26 Performance Analysis
The Jubilant Pharmova Q4 FY26 results reflect the company’s operational performance during the January to March 2026 quarter. The company delivered steady performance in line with sector trends. Jubilant Pharmova operates in the Pharmaceuticals and Contract Manufacturing sector, which is supported by India’s GDP growth above 6.5% and domestic demand tailwinds in FY26.
Revenue of Rs 2,290 crore was up 18.0% YoY. Strong revenue growth reflects market share gains and healthy demand.
Screen the best stocks on the Univest Screener.
Key Factors Driving Jubilant Pharmova Q4 FY26 Results
Revenue Performance
Revenue of Rs 2,290 crore in Jubilant Pharmova Q4 FY26 was up 18.0% YoY. The double-digit topline growth reflects strong end-market demand, market share gains, and favourable pricing conditions in the Pharmaceuticals and Contract Manufacturing sector. The January to March 2026 quarter is the year-end quarter, characterised by strong order execution and fiscal year-end activity across Indian corporates.
Profitability and Margin Analysis
The Jubilant Pharmova Q4 FY26 PAT of Rs 119 crore down 21.0% YoY. Stable profitability reflects consistent margin management.
Sector Tailwinds and India Macro Environment
The Pharmaceuticals and Contract Manufacturing sector saw constructive operating conditions in Q4 FY26. India’s macroeconomic environment, with GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption, supported demand across sectors. The Reserve Bank of India’s accommodative liquidity stance aided credit conditions. For Jubilant Pharmova, these macro and sectoral tailwinds provided a supportive backdrop in the January to March 2026 quarter.
FY27 Outlook
Following the firm results, management commentary on FY27 revenue guidance, margin trajectory, capex plans, and demand pipeline will be the key investor focus areas. The Pharmaceuticals and Contract Manufacturing sector benefits from India’s long-term growth story including urbanisation, infrastructure investment, and rising middle-class consumption. Consistent growth delivery and margin improvement remain the management’s strategic priorities.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on the company
What is Jubilant Pharmova Q4 FY26 net profit?
Ans. Jubilant Pharmova Q4 FY26 PAT of Rs 119 crore, down 21.0% YoY from Rs 151 crore in Q4 FY25. Results declared May 22, 2026, on a Consolidated basis. Verify from BSE/NSE audited filings.
What is Jubilant Pharmova Q4 FY26 revenue?
Ans. Jubilant Pharmova Q4 FY26 revenue from operations was Rs 2,290 crore, up 18.0% YoY. Verify complete financials from BSE/NSE filings.
When were Jubilant Pharmova Q4 FY26 results declared?
Ans. Jubilant Pharmova Q4 FY26 results were declared on May 22, 2026, at the board of directors meeting approving audited Q4 and full-year FY26 financial statements.
Is Jubilant Pharmova a good investment after Q4 FY26 results?
Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk tolerance. This article is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before investing in Jubilant Pharmova.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.
